Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608086 | 0.92 | MAPT (0.66) | MAPTNPSR1GLO1MAOBALDH1A1 | |
| SCHEMBL9475614 | 0.92 | MAPT (0.66) | MAPTNPSR1GLO1MAOBALDH1A1 | |
| SCHEMBL4608089 | 0.92 | MAPT (0.66) | MAPTNPSR1GLO1MAOBALDH1A1 | |
| SCHEMBL4608087 | 0.92 | MAPT (0.66) | MAPTNPSR1GLO1MAOBALDH1A1 | |
| SCHEMBL7250786 | 0.91 | MAPT (0.64) | MAPTNPSR1GLO1MAOBALDH1A1 | |
| SCHEMBL8464899 | 0.88 | MAPT (0.61) | MAPTNPSR1GLO1MAOBALDH1A1 | |
| SCHEMBL3131441 | 0.88 | MAPT (0.89) | MAPTNPSR1GLO1ALDH1A1RAB9A | |
| SCHEMBL8464902 | 0.88 | MAPT (0.61) | MAPTNPSR1GLO1MAOBALDH1A1 | |
| SCHEMBL3131439 | 0.88 | MAPT (0.89) | MAPTNPSR1GLO1ALDH1A1RAB9A | |
| SCHEMBL10386660 | 0.84 | MAPT (0.64) | MAPTNPSR1GLO1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0440324-B1 | Substituted beta-diketones and their use in the treatment of inflammatory bowel disease | ORION YHTYMAE OY (FI) | 2000-04-12 | — | — | EP | claimed |
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | claimed |
| US-5565491-A | FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| EP-0440324-A2 | Substituted beta-diketones and their use | ORION-YHTYMÀ OY (FI) | 1991-08-07 | — | — | EP | claimed |
| US-20230241078-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2023-08-03 | — | — | US | disclosed |
| US-20200246352-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2020-08-06 | — | — | US | disclosed |
| EP-3684352-A1 | VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT | CFM Pharma Holding BV (NL) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019059770-A1 | VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT | CFM PHARMA HOLDING B.V. (NL) | 2019-03-28 | — | — | WO | disclosed |
| US-20150335628-A1 | OLIGOMER-CALCIUM CHANNEL BLOCKER CONJUGATES | NEKTAR THERAPEUTICS | 2015-11-26 | — | — | US | disclosed |
| US-9132200-B2 | Oligomer-calcium channel blocker conjugates | NEKTAR THERAPEUTICS (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140323529-A1 | OLIGOMER-CALCIUM CHANNEL BLOCKER CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-10-30 | — | — | US | disclosed |
| US-3959292-A | HYPOTENSIVE AGENTS, CORONARY DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-25 | — | — | US | disclosed |
| US-3951994-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3951988-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3948923-A | HYPOTENSIVE, VASODILATION | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-06 | — | — | US | disclosed |
| US-3946026-A | HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-23 | — | — | US | disclosed |
| US-3939171-A | HYPOTENSIVE, VASODILATION | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | disclosed |
| US-3935220-A | VASODILATION, HYPOTENSIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-27 | — | — | US | disclosed |
| US-3935223-A | 2-Amino-1,4-dihydropyridine derivatives | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335628-A1 | OLIGOMER-CALCIUM CHANNEL BLOCKER CONJUGATES | ORAI1, CACNB2, CACNA1B | MAPT 292/4885NPSR1 682/4885GLO1 1121/4885 |
| US-20140323529-A1 | OLIGOMER-CALCIUM CHANNEL BLOCKER CONJUGATES | ORAI1, CACNB2, CACNA1B | MAPT 292/4885NPSR1 682/4885GLO1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.